



TML/BSE/NSE/2025-26/16

1st August, 2025

The Manager
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 530199

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: THEMISMED

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Meeting Commencement time : 03: 00 P.M.
Meeting Conclusion Time : 05: 00 P.M.

Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Friday, 1st August, 2025, have inter-alia transacted the following items of businesses:

1. Approved the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2025 together with the Limited Review Report issued by the Statutory Auditors, M/s. Krishna & Co., Chartered Accountants which are attached herewith.
2. Approved the appointment of Ms. Neha Thakore (DIN: 00893957) as an Additional Non-Executive Woman Independent Director of the company not liable to retire by rotation to hold office for a term of 5 (five) years w.e.f. 1st August, 2025 subject to the approval of members at the forthcoming Annual General Meeting.

Brief Profile of Ms. Neha Thakore as per Regulation 30 of the SEBI Listing Regulations is provided herewith as **Annexure I.**

3. Approved the appointment of Mr. Viraj Save as Executive President – Sales & Marketing (Senior Management Personnel) with effect from 1st August, 2025.

Requisite details as per SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is enclosed as **Annexure II.**

4. Fixed the record date i.e. 5th September, 2025 for the purpose of determining the entitlement of Members to receive final dividend for the financial year ended 31st March, 2025.

We request you to take the above on record please.

Thanking you,

Yours faithfully,

For **THEMIS MEDICARE LIMITED**

Pradeep Chandan
Director – Legal, Compliance & Company Secretary

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com



Annexure I

Disclosure under sub-para (7) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ms. Neha Thakore (DIN: 00893957):

Sr. No	Particulars	Details
1	Reason for change	Appointment as an Additional Non-Executive Woman Independent Director.
2	Date of appointment & term of appointment	Ms. Neha Thakore has been appointed as an Additional Non-Executive Woman Independent Director of the Company (not liable to retire by rotation) w.e.f. 1 st August, 2025 for a period of 5 (five) years, subject to the approval of the members at the forthcoming Annual General Meeting of the Company.
3	Brief profile (in case of appointment)	Ms. Neha Thakore is a graduate in Social Science from St. Xavier's College, Mumbai. She is a seasoned leader in the pharmaceutical industry, with over 25 years of experience in the Active Pharmaceutical Ingredients (API) business. She currently serves as the Managing Partner of Rifa Pharma and Chief Operating Officer & Director at Avik Pharmaceutical Ltd., where she oversees strategic growth, manufacturing and operations. Ms. Neha Thakore's career spans key roles in business development, operations management, and international regulatory affairs. She has also been instrumental in advancing sustainable practices and strengthening corporate governance across the industry. In addition to her executive role, she contributes actively to industry development through her positions as Chairperson of the IDMA POSH, HR & ESG Committees, and Vice Chairperson of the API Committee.
4	Disclosure of relationships between Directors (In case of appointment of a Director).	She is not related to any Directors of the Company.
5	Affirmation	Ms. Neha Thakore is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. She has not been convicted of any offence in connection with the promotion, formation or management of any company or LLP, nor found guilty of any fraud, misfeasance or breach of duty to any company under the Companies Act, 2013 or any previous Companies Act in the last five years.

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com



Annexure II

Disclosure under sub-para (7) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Mr. Viraj Save - Executive President – Sales & Marketing (Senior Management Personnel)

Sr. No	Particulars	Details
1	Reason for change	Appointment as Executive President – Sales & Marketing (Senior Management Personnel)
2	Date of appointment & term of appointment	1 st August, 2025 Term: Whole-time employment of the Company as an employee.
3	Brief profile (in case of appointment)	Mr. Viraj Save is a seasoned Sales and Marketing professional with over 35 years of leadership experience in the Indian pharmaceutical industry. He brings a rich blend of expertise across multiple therapy areas including Cardiology, Diabetes, Gastroenterology, Urology, Nutrition, Pain Management, Neuropsychiatry and Gynecology. Educational Background: • Master's in Marketing Management – NMIMS, Mumbai • B.Sc. (Chemistry) – Bhavan's College, Mumbai.
4	Disclosure of relationships between Directors (In case of appointment of a Director).	Not Applicable

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com

THEMIS MEDICARE LTD
CIN NO : L24110GJ1969PLC001590
Regd. Off. Plot No. 69-A, GIDC Indl, Estate, Vapi - 396195, Dist Valsad,
Gujarat. (T) 0260-2431447 / 0260-2430219,
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104,
Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the Quarter ended 30 June 2025

	Particulars	Standalone			
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year Ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income:				
1	Revenue from Operations (Net)	9,757.77	7,170.16	12,299.38	40,551.16
2	Other income	117.59	155.19	95.85	466.95
3	Total Income (1+2)	9,875.36	7,325.35	12,395.23	41,018.11
4	Expenses:				
	(a) Cost of materials consumed	1,242.99	1,897.50	2,351.94	7,630.85
	(b) Purchases of Stock-in-Trade	2,167.58	1,629.79	1,674.12	7,366.65
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	1,829.27	(1,468.47)	100.96	(1,798.44)
	(d) Employee benefits expense	2,484.91	2,545.09	2,159.50	9,637.58
	(e) Finance costs	247.02	245.04	235.87	1,003.93
	(f) Depreciation and amortization expense	255.28	253.15	240.61	992.87
	(g) Other expenses	3,040.77	3,143.94	3,094.66	12,808.31
	Total Expenses (II)	11,267.82	8,246.04	9,857.66	37,641.75
5	Profit/(loss) before exceptional items and tax (3-4)	(1,392.46)	(920.69)	2,537.57	3,376.36
6	Exceptional items [net] - Refer Note No. 5	(129.39)	-	-	-
7	Profit/(Loss) before tax (5+6)	(1,521.85)	(920.69)	2,537.57	3,376.36
8	Tax expense:				
	(a) Current Tax	-	(250.00)	640.00	830.00
	(b) Deferred Tax	15.52	103.79	26.10	154.21
9	Profit/ (Loss) for the Period (7-8)	(1,537.37)	(774.48)	1,871.47	2,392.15
10	OTHER COMPREHENSIVE INCOME				
	(a i) Items that will not be reclassified to profit & loss	(10.33)	(33.68)	(24.61)	(41.30)
	(a ii) Income tax relating to items that will not be reclassified to profit or loss	2.60	8.48	6.19	10.40
	(b) Items that will be reclassified to profit & loss	-	-	-	-
11	Total comprehensive income for the period (9+10)	(1,545.10)	(799.68)	1,853.05	2,361.25
12	Paid up Equity Share Capital (Face Value of Rs.1/- per Equity Share)	920.40	920.40	920.40	920.40
13	Other Equity (Excluding Revaluation Reserve)				27,811.14
	Earnings per share (EPS) (of Rs. 1 each)				
	(a) Basic	(1.67)	(0.84)	2.03	2.60
	(b) Diluted	(1.67)	(0.84)	2.03	2.59




THEMIS MEDICARE LIMITED

NOTES :

- 1) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on August 01, 2025.
- 2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable business segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 4) The Board of Directors of the Company, at its meeting held on November 18, 2024, had approved the Scheme of Amalgamation ("Scheme") between Gujarat Themis Biosyn Limited ("GTBL") and the Company and their respective shareholders under sections 230 to 232 and other applicable provisions of the Companies Act, 2013, subject to receipt of necessary regulatory and other approvals.

However, the Board of Directors of GTBL, at its meeting held on June 13, 2025 after evaluating new developments in the market decided to focus on its core business of fermentation-based pharmaceutical intermediates and active pharmaceutical ingredients and decided to revisit all its strategic options. Consequently, the GTBL Board reconsidered its earlier decision of merger and resolved not to proceed with the proposed merger. Accordingly, the GTBL Board has approved the withdrawal of the Scheme as permitted under clause 21 of the Scheme.

In alignment with this decision, the Board of Directors of the Company has also resolved to withdraw the said Scheme of Amalgamation.

Pursuant to this, the Company shall continue to focus on its core domestic formulations business with the objective of achieving long-term sustainable growth.

- 5) The company has received an approval for struck off M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. Accordingly, the company has provided for Investment Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs in the Financial Statement as the Company is in the process of obtaining approval from the Reserve Bank of India (RBI) under the Foreign Exchange Management Act (FEMA), 1999, for writing off the said investments.

The company has disclosed the Investments, receivables and advances provided for, as an exceptional item in the Statement of Profit and Loss in accordance with Ind AS 1 and applicable accounting principles. On obtaining necessary approvals from RBI for striking off the said foreign subsidiary, as per the provisions of the FEMA and applicable ODI regulations, the amounts will be written-off.

- 6) The figures of the quarter ended March 31, 2025 of the previous financial year is balancing figures between audited figures of the full financial year and published year-to-date figures for the nine months ended December 31, 2024.
- 7) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

Place : Mumbai
Date : 1st August, 2025

THEMIS MEDICARE LTD
CIN NO : L24110GJ1969PLC001590
 Regd. Off. Plot No. 69-A, GIDC Indl, Estate, Vapi - 396195, Dist Valsad,
 Gujarat. (T) 0260-2431447 / 0260-2430219,
 Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104,
 Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the Quarter ended 30 June 2025

(Amount in INR Lakhs)

	Particulars	Consolidated			
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year Ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income:				
1	Revenue from Operations (Net)	9,757.77	7,170.16	12,299.38	40,551.16
2	Other income	117.59	155.19	95.85	466.95
3	Total Income (1+2)	9,875.36	7,325.35	12,395.23	41,018.11
	Expenses:				
	(a) Cost of materials consumed	1,242.99	1,897.50	2,351.94	7,630.85
	(b) Purchases of Stock-in-Trade	2,167.58	1,629.79	1,674.12	7,366.65
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	1,829.27	(1,468.47)	100.96	(1,798.44)
	(d) Employee benefits expense	2,484.91	2,545.09	2,159.50	9,637.58
	(e) Finance costs	247.02	245.03	235.87	1,003.95
	(f) Depreciation and amortization expense	255.28	253.15	240.61	992.87
	(g) Other expenses	3,041.19	3,144.68	3,095.30	12,809.70
	Total Expenses (II)	11,268.24	8,246.77	9,858.30	37,643.16
	Profit/ (Loss) before exceptional items, share of				
5	Profit/(Loss) of associates and joint venture and tax (3-4)	(1,392.88)	(921.42)	2,536.93	3,374.95
6	Exceptional items [net]	-	-	-	-
7	Profit/ (Loss) before share of Profit/ (Loss) of associates and joint venture and tax (5+6)	(1,392.88)	(921.42)	2,536.93	3,374.95
8	Add: Share of Profit/ (Loss) of associates and a joint venture for the Period	(13.57)	(191.24)	597.64	592.54
9	Profit/ (Loss) before tax (7 + 8)	(1,406.45)	(1,112.66)	3,134.57	3,967.49
10	Tax expense:				
	(a) Current Tax	-	(250.00)	640.00	830.00
	(b) Deferred Tax	15.52	103.79	26.10	154.21
11	Profit/ (Loss) for the Period (9-10)	(1,421.97)	(966.45)	2,468.47	2,983.28
	Attributable to :				
	Equity holders of the Parent	(1,421.96)	(966.44)	2,468.48	2,983.30
	Non - Controlling interests	(0.01)	(0.01)	(0.01)	(0.02)
12	OTHER COMPREHENSIVE INCOME				
	(a i) Items that will not be reclassified to profit & loss	(10.33)	(33.68)	(24.61)	(41.30)
	(a ii) Income tax relating to items that will not be reclassified to profit or loss	2.60	8.48	6.19	10.40
	(a iii) Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method	0.29	1.35	(0.19)	1.18
	(b) Items that will be reclassified to profit & loss	4.64	0.79	-	0.07
13	Total comprehensive income for the period (11+12)	(1,424.77)	(989.51)	2,449.86	2,953.63
	Attributable to :				
	Equity holders of the Parent	(1,424.76)	(989.50)	2,449.87	2,953.65
	Non - Controlling interests	(0.01)	(0.01)	(0.01)	(0.02)
14	Paid up Equity Share Capital (Face Value of Rs.1/- per Equity Share)	920.40	920.40	920.40	920.40
15	Other Equity (Excluding Revaluation Reserve)				36,042.59
16	Earnings per share (EPS) (of Rs. 1 each)				
	(a) Basic	(1.54)	(1.05)	2.68	3.24
	(b) Diluted	(1.54)	(1.05)	2.68	3.24

 

THEMIS MEDICARE LIMITED

NOTES :

- 1) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on August 01, 2025.
- 2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 4) The Board of Directors of the Company, at its meeting held on November 18, 2024, had approved the Scheme of Amalgamation ("Scheme") between Gujarat Themis Biosyn Limited ("GTBL") and the Company and their respective shareholders under sections 230 to 232 and other applicable provisions of the Companies Act, 2013, subject to receipt of necessary regulatory and other approvals.

However, the Board of Directors of GTBL, at its meeting held on June 13, 2025 after evaluating new developments in the market decided to focus on its core business of fermentation-based pharmaceutical intermediates and active pharmaceutical ingredients and decided to revisit all its strategic options. Consequently, the GTBL Board reconsidered its earlier decision of merger and resolved not to proceed with the proposed merger. Accordingly, the GTBL Board has approved the withdrawal of the Scheme as permitted under clause 21 of the Scheme.

In alignment with this decision, the Board of Directors of the Company has also resolved to withdraw the said Scheme of Amalgamation.

Pursuant to this, the Company shall continue to focus on its core domestic formulations business with the objective of achieving long-term sustainable growth.

- 5) The company has received an approval for struck off M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. Accordingly, the company has provided for Investment Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs in the Financial Statement as the Company is in the process of obtaining approval from the Reserve Bank of India (RBI) under the Foreign Exchange Management Act (FEMA), 1999, for writing off the said investments.

The company has disclosed the Investments, receivables and advances provided for, as an exceptional item in the Statement of Profit and Loss in accordance with Ind AS 1 and applicable accounting principles. On obtaining necessary approvals from RBI for striking off the said foreign subsidiary, as per the provisions of the FEMA and applicable ODI regulations, the amounts will be written-off.

- 6) The figures of the quarter ended March 31, 2025 of the previous financial year is balancing figures between audited figures of the full financial year and published year-to-date figures for the nine months ended December 31, 2024.
- 7) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

Place : Mumbai
Date : 1st August, 2025

**INDEPENDENT AUDITORS' REVIEW REPORT ON THE UNAUDITED STANDALONE
QUARTERLY AND YEAR -TO-DATE FINANCIAL RESULTS OF THE COMPANY
PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS), REGULATIONS, 2015, AS AMENDED**

Review Report to
The Board of Directors
THEMIS MEDICARE LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of THEMIS MEDICARE LIMITED ("the Company") for the quarter ended 30th June 2025 ("the Statement") and being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the company at their meeting held on 01st August 2025 and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS 34") prescribed under Section 133 of the Companies Act 2013 and other Accounting Principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying the analytical and other review procedures and thus provides



less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies thereon, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Krishaan & Co.,
Firm Reg. No.001453S
Chartered Accountants

K. Sundarajan

K Sundarrajan
Partner

Membership No. 208431

UDIN: 25208431 BMIFX57579



Date : 01st August 2025
Place: Mumbai

**INDEPENDENT AUDITORS' REVIEW REPORT ON THE UNAUDITED CONSOLIDATED
QUARTERLY AND YEAR -TO-DATE FINANCIAL RESULTS OF THE COMPANY
PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS), REGULATIONS, 2015, AS AMENDED**

Review Report to
The Board of Directors
THEMIS MEDICARE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of THEMIS MEDICARE LIMITED ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as ("the Group")), and its share of the net profit after tax and total comprehensive income of its associates for the quarter ended 30th June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations and which has been initialled by us for identification purposes. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we



would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We have also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Subsidiaries

- a) Themis Chemicals Private Limited
- b) Artemis Biotech Limited
- c) Dr. Themis Private Limited

Associates

- a) Gujarat Themis Biosyn Limited
- b) Long Island Nutritionals Private Limited

Associate (Joint Venture)

- a) Richter Themis Medicare (India) Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 3 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs.9.30 lakhs as at 30th June 2025 and total revenues of Rs.Nil, total net loss after tax of Rs.0.42 lakhs and total comprehensive income of Rs.NIL, for the quarter ended 30th June 2025.



The consolidated unaudited financial results also includes 2 Associates and 1 Joint Venture, whose interim financial information reflects total assets of Rs. 48,727.15 lakhs as at 30th June 2025 and total revenues of Rs. 5,241.75 lakhs, total net profit after tax of Rs. 449.61 lakhs and total comprehensive income of Rs. 1.27 lakhs for the quarter ended 30th June 2025. These financial information have been reviewed by other auditors whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, are based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of the above matter.

7. We draw attention to Note No. 5 of the Consolidated Financial Statements, which indicates that the Company has provided for Investments amounting to Rs. 0.76 lacs in wholly-owned Subsidiary Company and Receivables and Advances amounting to Rs. 128.63 lacs due from its wholly-owned subsidiary, M/s. Carpo Medicals Limited (UK), on account of approval of Strike Off of the Company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. The Company is in the process of obtaining approval from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 for writing off of the said investment.

Our conclusion on the Statement is not modified in respect of the above matter

For Krishaan & Co.,
Firm Reg. No.001453S
Chartered Accountants

K Sundarajan

K Sundarajan

Partner

Membership No. 208431

UDIN: 25208431BMTFXR4156

Date : 01st August 2025

Place: Mumbai

